Q2 Korea Biotech Roundup: Licensing Deals End, Trials Progress, IPOs Recover

Orum Asset Discontinued, TiumBio Asset U-Turned

 
• By Jung Won Shin
  
Deals, IPOs and clinical trials
Large Global Out-Licensing Deals, Stock Rallies Improve IPO Sentiment In South Korea (Shutterstock/AI generated image)

More from South Korea

More from Focus On Asia